Resources


June 24, 2020

TEXAS A&M TESTS COVID-19 VACCINE CANDIDATES FOR IBIO, INC.

by tamus | Jun 24, 2020 | System News       Chancellor Sharp praises partnership between university, biotech firm   COLLEGE STATION, Texas — A team of scientists at Texas A&M is working on two COVID-19 vaccine candidates that could be mass produced ...

Continue Reading

June 24, 2020

iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates

iBio Granted 18 Months of Free Access to IBM’s Clinical Trial Management System NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology ...

Continue Reading

June 4, 2020

iBio Announces Second COVID-19 Vaccine Program

IBIO-201, a subunit vaccine combining SARS-CoV-2 spike protein antigens with the Company’s proprietary LicKM booster technology, advances to preclinical immunization studies with the potential for rapid manufacturing scale-up in

Continue Reading

April 27, 2020

iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™

- Company Expands Involvement in the Manufacturing USA® Network, Joining the National Institute for Innovation in Manufacturing Biopharmaceuticals -  

Continue Reading

April 9, 2020

iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute

- The Nonprofit Will Help Lead Pre-Clinical Development and Clinical Trial Oversight - NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and ...

Continue Reading
1 2 3